all projects

Value added
of German
pharmaceutical exports

Client

Roche

Year

2023


The pharmaceutical industry is one of Germany’s most important export industries. In recent years, the export of pharmaceutical products has seen above-average growth compared to the other export sectors. In addition, research and development play a prominent role for pharmaceutical companies.

Our new study for Roche focuses on these two aspects. It examines the extent to which the German pharmaceutical industry is particularly value-added intensive and innovative in its exports. 

Pharmaceutical exports generate above-average value-added 

Compared to those in the other industries, German pharmaceutical exports are characterised by above-average value-added intensity and growth dynamics. This means that the export of pharmaceutical products (for example, worth one million euros) is linked to more domestic value added and jobs than the average German export of one million euros.

In an international comparison, the German pharmaceutical industry is shown to be one of the most important players on the world market and has been able to maintain its share of world exports in recent years.

Germany's share of global pharmaceutical patents is declining

In terms of research, the German pharmaceutical industry is losing ground on its international competitors:

  • In terms of research and development expenditure in relation to sales, the pharmaceutical industry is among the two most research-intensive German industrial sectors. Their absolute research expenditure has also risen at an above average rate in recent years.
  • The high global innovation dynamics in the pharmaceutical research sector is also reflected in patents: during the period under review, the number of pharmaceutical patents increased twice as much as the total number of patents worldwide.
  • However, Germany as a research location was not able to keep up with this dynamic. The German share of worldwide patents has fallen noticeably in recent years, due, in particular, to a high increase in the patent activity of the Chinese and Korean research locations.
  • On the one hand, this indicates that global pressure for innovation is likely to remain high in the coming years. On the other, this is a warning signal: in the future, a relative loss of importance in terms of innovation could also lead to a relative loss of importance on the market side – marked by shrinking world export shares. 

Our approach

For this detailed investigation of the German pharmaceutical industry in a national and international comparison, we relied on the available statistical data. This was then analysed with the help of the Prognos model landscape.

Links and downloads

To the study (PDF in German)

Further information, in German (Roche website)

Project team: Dr Georg Klose, Dr Andreas Sachs, Johann Weiss 

Latest update: 07.12.2023

Do you have questions?

Your contact at Prognos

Johann Weiß

Senior Project Manager

View profile

Mehr Studien & Projekte zu diesem Thema

More studies & projects on this topic

A greener economy through green finance

2024
| Project

With green finance, greenhouse gases in Austria can be reduced by up to four per cent by 2040 – in the bond market alone. This is the result of our study commissioned by the Ministry for Climate Action.

Support for the Saxony-Anhalt Citizens' Advisory Board on Structural Change

ongoing
| Project

Prognos supports the Citizens' Advisory Council in incorporating the perspectives of the population into decision-making processes and advises the responsible staff unit of the State Chancellery.

Resilience and sovereignty of German industry

ongoing
| Project

German industry is dependent on raw materials and preliminary products from abroad. On behalf of the Netzwerk Zukunft der Industrie e. V., Prognos analyses the supply chains and provides recommendations for action.

North Rhine-Westphalia Green Economy Report 2024

2024
| Project

The green economy is a driving force in North Rhine-Westphalia. Both gross value added and the number of people in employment are increasing at a faster rate than in other sectors of the economy.

Conversion of the automotive industry: How employment is changing

2024
| Project

The automotive industry is undergoing fundamental change. How does this effect employment? And what will it mean for the individual professions? We investigated this on behalf of the VDA.

Green Tech Atlas 2025

ongoing
| Project

On behalf of the Federal Ministry for the Environment, Prognos compiled the Green Tech Atlas 2025. The atlas provides a comprehensive overview of the cross-sectional environmental tech-nology and resource efficiency industries.

The economic and social situation of the creative industries

2024
| Project

On behalf of the Federal Ministry of Education, Science and Research and the Federal Government Commissioner for Culture and the Media, Prognos and partner analysed the economic and social situation of self-employed solo artists in creative professions.

Impact of global crises on regional labour markets

ongoing
| Project

A shrinking workforce, digitalisation and decarbonisation: Prognos examines the specific effects of global trends on regional labour markets.

Long-term care financing scenarios

2024
| Project

Higher numbers of care-dependent persons and increasing costs - our aging population is putting long-term care insurance to the test. A new analysis shows what the future financial require-ments will be.

Evaluation of the ERDF programmes of several federal states

ongoing
| Project

How effectively do the federal states utilise ERDF funding? Prognos supports various federal states with the evaluation of their ERDF programmes.

About us

Prognos – Providing Orientation.

Prognos is one of the oldest economic research centres in Europe. Founded at the University of Basel, Prognos experts have been conducting research for a wide range of clients from the public and private sectors since 1959 – politically independent, scientifically sound.

Learn more